Treatment
Immunoglobulins clinical trials
We’re tracking 79 recruiting studies that include Immunoglobulins, each written for real people, not researchers, below.
Recruiting studies
- NCT05681975Recruiting
Test whether antibodies relate to food reaction symptoms
This study looks at adults who have symptoms they believe are caused by reactions to foods. Researchers will test immune blood markers (antibodies) to better understand what may be driving these symptoms and whether that information could help people in the future.
MadridAges 18–80 - NCT05678621RecruitingPhase 2/Phase 3
Testing stopping or extending immune treatment to prevent infections
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
Garran, Australian Capital TerritoryAges 18 years+ - NCT07202052RecruitingPhase 2/Phase 3
Antibiotics or immunoglobulin for infections in blood cancer
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
Adelaide, South AustraliaAges 18 years+ - NCT06935357RecruitingPhase 3
Felzartamab infusions for IgA nephropathy
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
Little Rock, ArkansasAges 18 years+ - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT05810480Recruiting
Predicting steroid-dependent liver injury with blood test
This study looks at whether a specific blood marker can predict which patients with liver inflammation will need long-term steroid treatment. It may help doctors decide the best treatment for you if you have unexplained liver injury.
AachenAges Any age - NCT04589299RecruitingPhase 4
Subcutaneous immune globulin for newly diagnosed CIDP
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
AalborgAges 18 years+ - NCT04656184RecruitingPhase 3
Anakinra vs IVIG for kids who don’t respond to first IVIG
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
Le Kremlin-Bicêtre, Val De MarneAges 3 months–17 years - NCT04662723RecruitingPhase 4
Personalized treatment for IgA kidney disease
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
Bari, BAAges 18 years+ - NCT04663204RecruitingPhase 2
Sparsentan study for IgA kidney disease in adults
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
Cambridge, EnglandAges 18 years+ - NCT04881682RecruitingPhase 2
Testing blood-cleansing vs immunoglobulin for CIDP
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
Ulm, Baden-WurttembergAges 18 years+ - NCT05072691Recruiting
Tests spinal fluid proteins to predict multiple sclerosis outlook
This study checks specific proteins in spinal fluid to see whether they can predict how multiple sclerosis (or related symptoms like optic neuritis) may go over time. It may help doctors better estimate prognosis using results from tests you may already be having.
BrusselsAges 18 years+ - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06158854RecruitingPhase 1/Phase 2
Study of etentamig (ABBV-383) for AL amyloidosis
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
Miami, FloridaAges 18 years+ - NCT06373211RecruitingPhase 2
Early immunotherapy for nerve damage linked to anti-Hu antibodies
This trial tests whether a combination of three immune-suppressing drugs (IVIg, cyclophosphamide, and methylprednisolone) given early can improve balance and sensation in people with a rare nerve condition caused by anti-Hu antibodies. The goal is to stop or slow the nerve damage before it gets worse.
ParisAges 18 years+ - NCT06533098RecruitingPhase 3
Nipocalimab vs IVIG for FNAIT in pregnancy
This study tests a new medicine called nipocalimab compared to standard IVIG treatment for pregnant women who are at risk of a serious condition where the mother's antibodies attack the baby's platelets (FNAIT). The goal is to see if nipocalimab can prevent complications like bleeding in the baby.
Birmingham, AlabamaAges 18–45 - NCT06952426Recruiting
IgA Nephropathy app study for patients and caregivers
This study uses a mobile app to track how IgA nephropathy (IgAN) affects daily life and what treatments people use. It’s open to patients and their caregivers to help researchers learn more about the disease.
Boston, MassachusettsAges 18 years+ - NCT06954441RecruitingPhase 3
A new immune therapy for people with low IgG
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
Recife, PernanbucoAges 2 years+ - NCT07013370Recruiting
Preventing CMV in Children After Stem Cell Transplant
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
TriesteAges 1 month–18 years - NCT07202065RecruitingPhase 2/Phase 3
Preventing infections with antibiotics or immunoglobulin in blood disorders
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Adelaide, South AustraliaAges 18 years+ - NCT07202078RecruitingPhase 2/Phase 3
Starting immunoglobulin for infection prevention in hematology
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
Adelaide, South AustraliaAges 18 years+ - NCT07202091RecruitingPhase 2/Phase 3
Stopping or extending immunoglobulin therapy to prevent infections
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
Adelaide, South AustraliaAges 18 years+ - NCT07233213RecruitingPhase 3
IVIG for chronic low platelet condition
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Ankara, AltındağAges 18–65 - NCT07299695RecruitingPhase 3
IVIG for sudden worsening of IPF
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
PátraiAges 18 years+
What Immunoglobulins is being studied for
Conditions with recruiting Immunoglobulins studies.
Common questions
- Are there clinical trials studying Immunoglobulins?
- Yes. Clin2 currently lists 79 recruiting studies that include Immunoglobulins, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Immunoglobulins trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Immunoglobulins an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Immunoglobulins or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.